Evaluation of Target Organs Damage in Hypertensive Patients (PreVENT-A GP)

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

no Known Cardiovascular
Hypertensive
no Known Renal Disease
Target Organs Damage

Study type

Observational

Funder types

Industry

Identifiers

NCT01055353
NIS-CFR-DUM-2009/2

Details and patient eligibility

About

Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control

Enrollment

1,857 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

diagnosis of essential hypertension (treated or untreated); HT not discovered on the day of the consultation; no documented clinical cardiovascular or renal disease.

Exclusion criteria

-

Trial contacts and locations

908

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems